We describe here the United Kingdom (UK) response following the recent international recall of an organ preservation fluid owing to potential Bacillus cereus contamination. This fluid is used for the transport of solid organs and pancreatic islet cells for transplant. We detail the response mechanisms, including the initial risk stratification, investigatory approaches, isolate analysis and communications to professional bodies. This report further lays out the potential need for enhanced surveillance in UK transplant patients.
Current incident
On 23 March 2012, Bristol-Meyers Squibb notified the Medicines and Healthcare products Regulatory Agency -an executive agency of the Department of Health, England -of possible contamination of their product ViaSpan, an organ preservation fluid used for the transport of solid organs (liver, kidney, bowel and pancreas) and pancreatic islet cells for transplant [1] . Bacillus cereus contamination from the production line was identified on 16 March 2012 through a simulated production run in February 2012 that used bacterial growth medium instead of ViaSpan [2] , designed to be a worst-case challenge to the microbiological integrity of the production process [3] . The contaminant load is unknown. This routine production simulation run had last been performed in July 2011, with satisfactory results. To date, there has been no evidence of contamination in batches of ViaSpan produced before or since contamination was found in the simulated production run in February 2012. Nevertheless, a precautionary international recall of ViaSpan was issued to relevant regulatory authorities on 29 March 2012 and to product end-users on 30 March 2012 [4] . Investigations by the manufacturer concluded that the most probable cause was a manufacturing failure [5] .
Background
B. cereus is a well-known cause of food poisoning; however, it can also cause serious invasive disease including bacteraemia, septicaemia, endocarditis, osteomyelitis, pneumonia, brain abscess, and meningitis in severely immunocompromised patients, such as those with haematological malignancy, and in patients with indwelling vascular catheters [6] . Previous contamination of medical fluids [7] and devices [8] with B. cereus has been reported.
United Kingdom response
A coordinated response involving the Medicines and Healthcare products Regulatory Agency (MHRA), NHS Blood and Transplant (NHSBT) and the Health Protection Agency (HPA) was undertaken to quantify the potential risks to patients; the Department of Health and other United Kingdom (UK) devolved nations' health administrations were also involved. The different organisations liaised via regular teleconferences, meetings and email, ensuring all information was readily available in adequate time to be sent out to the transplant community by way of a daily email. A risk assessment was conducted for patients already transplanted with organs transported in potentially contaminated fluid and for those who could potentially be affected by the remaining ViaSpan stock. The continued use of implicated batches of ViaSpan was weighed against the risk of deferred transplantation resulting from the lack of an immediately available licensed alternative. Despite the potential contamination of ViaSpan with B. cereus and given the scarcity of donor organs and high mortality of patients on waiting lists for solid organ transplants, it was deemed that patients were at a much greater risk through not receiving a transplant than by the continued use of a potentially contaminated product.
Advice was issued to clinicians with responsibilities for transplant patients about alternative fluids. Where no suitable alternative was available, the manufacturer's advice that the solution could be used with caution was supported, together with advice to send a sample of fluid from any implicated batch of Viaspan for culture, to inform the surgical and renal teams of the results, to remain vigilant for signs of infection or transplant rejection, and to consider modifying prophylactic or therapeutic antimicrobial administration to cover B. cereus infection [9] . B. cereus produces multiple betalactamases and is commonly, though variably, resistant to penicillins, including beta-lactamase inhibitor combinations, carbapenems and cephalosporins.
Surveillance data
Routine laboratory data on reported cases of either B. cereus or all Bacillus species blood culture isolates in the UK showed no increase in systemic infections since July 2011 (Table 1) Of the small numbers of clinical B. cereus isolates with recorded clinical information that were sent to HPA reference laboratories for further identification (n=24), none was reported as being from a transplant patient (Table 2) . A large proportion of isolates were from patients with probable haematological or other malignancy. These are highly immunosuppressed patients and it is likely that referral of these samples reflects the fact that clinicians appropriately recognise B. cereus as a possible pathogen with the potential for serious morbidity or mortality rather than a sporadic contaminant in this context. The same approach should be applied to solid organ transplant patients.
As invasive infection with opportunistic Bacillus species (apart from B. anthracis) is not subject to mandatory notification in the UK, transplant centres were also requested to determine from local laboratories whether there had been any B. cereus infections in patients since mid-2011. NHS Blood and Transplant also reviewed similar information within their clinical reporting system and did not note any increase in adverse events since July 2011. It is plausible, though unlikely, that transmission of B. cereus may be missed because transplant recipients are given appropriate prophylactic antimicrobials.
Databases in solid organ transplant centres were interrogated for possible linkages with laboratory reports of isolation of B. cereus. Of five centres that routinely culture fluids, only one reported detection of Bacillus species from July 2011 onwards. This was a lower frequency than that for the preceding six months, and Bacillus species were isolated only from enrichment cultures (with additional growth factors) at 25 °C, as opposed to standard blood culture incubation at 37 °C (Table 3) . Thus there is currently no evidence from any existing surveillance system of any increase in B. cereus bacteraemias or of any other infections in transplant patients since July 2011.
Bacillus cereus isolates
Six isolates from the bacterial growth medium were forwarded in duplicate by the manufacturer to the HPA for confirmation, typing and antimicrobial susceptibility testing to ensure that appropriate advice was available to healthcare providers. The selection method for these isolates was unclear. The isolates were confirmed as B. cereus by a combination of 16S and gyrase B gene sequencing and phenotypic tests, which included confirming the absence of parasporal crystals [11] . The six isolates were subtyped by fluorescent amplified fragment length polymorphism (fAFLP) analysis and two very similar profiles were obtained, indicating that all isolates belonged to one of two closely related genetic groups (data not shown). The minor band differences may be due to single nucleotide polymorphism(s), however, and the two fAFLP types may actually represent the same strain.
In vitro studies using Etests on Iso-Sensitest agar [12] showed that the isolates were resistant to penicillins and extended-spectrum cephalosporins, reflecting beta-lactamase production. Despite high activity of meropenem in vitro (minimum inhibitory concentrations (MICs) ≤0.064 mg/L), concerns remain over inducible resistance since BcII -a chromosomal metallo-betalactamase that is widespread in B. cereus -has carbapenemase activity [13] [14] [15] . Where possible, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [16] were followed in interpreting MICs; however, there are no specific breakpoints for B. cereus.
The isolates were not susceptible to vancomycin (MICs 4 mg/L) and, unusually, also were resistant to daptomycin (MICs 2-4 mg/L), suggesting differences in membrane composition compared with other collections of Bacillus species reported to be susceptible (MIC 50 and MIC 90 values of 0.25 and 1 mg/L, respectively) to this lipopeptide [17] .
Risk management
A bactericidal agent would be preferred to a bacteriostatic agent in immunosuppressed patients. The six isolates from the bacterial growth medium were susceptible to the following antibacterical agents: ciprofloxacin (MICs ≤0.25 mg/L), gentamicin (MICs ≤0.5 mg/L), and, with the earlier caveat, meropenem. They also were susceptible to tetracyclines (rank order of MICs: tetracycline, ≤0.25 mg/L; doxycycline, ≤0.125 mg/L; tigecycline, ≤0.06 mg/L) and to linezolid (MICs ≤0.5 mg/L), which are all bacteriostatic. These susceptibilities were included in a detailed rapid risk assessment produced by the European Centre for Disease Prevention and Control (ECDC), to ensure a harmonised European approach to procurement of alternative supplies, surveillance and clinical management [18] .
Bacteriological culture of the implicated Viaspan batches is recommended for each transplant, with any positive cultures being reported to NHS Blood and Transplant [19] . Ongoing consultation with the manufacturer will investigate the root cause of B. cereus ingress into the production line, which will inform risk assessment, alongside further validation of the integrity of the production process.
The manufacturer notified all countries in the EU and European Economic Area that used the product, and a rapid alert notification was issued by the Austrian Medicines Authority on 29 March 2012 to further Three-month moving average for isolates from blood culture Three-month moving average for isolates from clinical sites other than blood a LabBase obtains data from all National Health Service laboratories by an automated data extract with manual final approval. It records only positive results for selected organisms (n=2,500) and is used to generate exceedance scores [10] .
advise EU Member States of the recall of the product [20] ; at present we have no further information on the response of other countries. The proposed action was to recall implicated fluids if alternative products were available. If no alternative product was available, the manufacturer would contact the country to discuss maintenance of the existing supply. The Medicines and Healthcare products Regulatory Agency also notified all Member States' medical device regulatory authorities about the recall.
Supply chains were also managed to ensure that suitable alternatives were sourced, and perfusion protocols amended to reflect the change in transplant transport fluid.
Conclusions
This incident underscores the need for robust structured surveillance of solid organ transplant patients, to include reporting of adverse incidents and infections, as acknowledged by the recent EU directive [21] . This sets common standards for organ donation and transplantation across Europe, including mandatory reporting and management systems for serious adverse events. a These isolates are referred by microbiologists for confirmation and antimicrobial susceptibility testing, the criteria for referral being based on clinician interest or concern. Thus, they represent a subset of total LabBase isolates. LabBase obtains data from all National Health Service laboratories by an automated data extract with manual final approval. It records only positive results for selected organisms (n=2,500) and is used to generate exceedance scores [10] . Table 3 Bacillus species isolated, data from reporting transplant 
